Based on the three definitions of trastuzumab resistance,21 the PICTURE study, a phase II trial of pyrotinib plus capecitabine for HER2‐positive advanced breast cancer that is trastuzumab‐resistant, also performed a subgroup analysis and found that patients who progressed within 12 months after completion of adjuvant/neoadjuvant trastuzumab therapy had the longest mPFS of 17.8 months compared with those who progressed during adjuvant/neoadjuvant trastuzumab therapy and those who progressed within 6 months of initiating trastuzumab therapy in the advanced stage. Here, ERBB2 is linked to breast carcinoma.